A n increase in AD use occurred in Canada in the 1990s, 1 continuing into the first part of the 21st century. 2 Such an increase has several possible explanations: ADs may be increasingly used for treatment of MDE, increasingly used for indications other than MDE, or people may be staying on ADs longer. Pharmacoepidemiologic data cannot decisively disentangle these various explanations, but can provide useful information on trends and the frequency of use. The objective of our study was to provide updated estimates of the frequency of AD treatment of MDE.
estimated response rate to 2006 was 77.0%. 3 The 1994 baseline interviews were conducted in person (75%), but 99% of the follow-up interviews take place over the phone. The 1994 NPHS sampling was integrated with another Statistics Canada study, the National Longitudinal Study of Children and Youth. The longitudinal cohort therefore includes children who were aged 0 to 12 years in 1994. The analyses presented here are restricted to respondents aged 12 years and older at each cycle. Because the cohort is refreshed each year by younger respondents entering the 12 years or older age range, the age of the sample has not changed very much during follow-up.
In the NPHS, the CIDI-SFMD was used to assess MDE. The CIDI-SFMD is scored with a predictive algorithm, providing about a 90% predictive value for MDE. The same algorithm requires endorsement of 5 symptom-based criteria during the same 2-week period. The CIDI-SFMD also included an item asking respondents to report the number of weeks in the year preceding an interview in which they were depressed. The NPHS interview also asks respondents to retrieve containers for all medication taken in the past 2 days and obtains a record of these medications.
Traditionally, the frequency of AD treatment is estimated as the proportion of respondents with a recent (past-year) MDE who are also taking an AD. This symptom-based approach neglects the possibility of successful treatment outcomes. Current guidelines indicate that long-term AD treatment may be useful for patients at high risk of relapse 4 so expectation holds that many patients with successful treatment outcomes may take ADs long after the resolution of their most recent episodes. Beck and Patten 5 proposed a procedure for adjusting the traditional calculation to account for the possibility of successful treatment. The approach involves adding respondents who may have been successfully treated (that is, respondents taking ADs but without a recent MDE) to the numerator and denominator of the calculated proportion. 5 To apply this adjustment, we identified a subset of respondents without MDE in the 2006 interview who nevertheless reported taking an AD in 2006. Within this group, respondents who may have been successfully treated were those respondents meeting any one of the following criteria: had prior episode(s) detected on the CIDI-SMFD between 1994 and 2004, reported being diagnosed with a depressive disorder by a health professional, or reported a past history of depressive episodes in response to an item included in the 2004 interview: "Have you ever had one or several episodes of being sad, depressed, discouraged, or uninterested most of the day, for several days, weeks and longer?" Sampling weights provided by Statistics Canada and an associated bootstrap procedure for variance estimation were used to account for sampling design effects. All analyses were conducted using Stata, version 9.0. 6 Our study was approved by the University of Calgary Conjoint Health Research Ethics Board. Table 1 reports the frequency of AD use by past-year MDE status. The frequency of use has continued to increase in those without a past-year MDE but there is no apparent increase in recent years among those with a past-year MDE. In the early cycles of the NPHS, a greater frequency of use of ADs was seen among women. For example, in the first cycle (1994), 6.5% of men (95% CI 2.1 to 10.9) and 14.3% of Figure 1 presents the unadjusted frequencies of AD use in respondents with past-year episodes, stratified by sex. Table 2 reports the frequency of AD use among respondents with MDE, by the number of reported weeks depressed during the year preceding the NPHS interviews. The frequency of use increases with increasing duration and also tends to be higher in the second half of the follow-up interval. This observation is consistent with the idea that some MDEs occurring in community populations may be brief and self-limited and that treatment may be less often sought or accessed for such episodes. However, the treatment frequency remains at about 40% in recent cycles, even among people reporting more than 6 months of depression in the preceding year. There were 502 respondents who reported taking an AD in the 2006 interview and who did not have an MDE in the preceding year. Evidence of a past history of depression (as defined above) was found in 332 respondents (weighted frequency 63.9%, 95% CI 58.4% to 69.3% 
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The unadjusted frequency of treatment in respondents with past-year MDE was lower than a previously reported estimate of 40.4% from the CCHS. 2 This inconsistency probably relates to different questions having been used to assess AD use (past 2 days in the NPHS, compared with past year in the CCHS). The 2005 US Medical Expenditure Panel Survey reported a 10.1% annual rate of AD use in the US general population, representing the frequency of use in a year rather than at a point in time. 7 Attrition from the longitudinal cohort may have affected the results. However, the rate of attrition was similar when compared between respondents taking and not taking an AD in 1994. Among respondents aged 12 years and older in 1994 who were taking an AD at that time, 50.8% subsequently completed all of the NPHS interviews up to 2006, compared with 51.0% of people in the same age category who were not taking an AD in 1994. The frequency of completion of all interviews is lower than the nonresponse rate cited above because respondents who die or are institutionalized during successful follow-up are not regarded as being lost to followup when the NPHS response rate is calculated. A vulnerability to bias could be introduced by the use of telephone interviews during NPHS follow-up if people are more or less likely to disclose medication use over the telephone. Another limitation of the NPHS is its use of a past-year diagnostic assessment in interviews that are spaced 2 years apart. Some episodes may have been missed as a result, which could According to a recent US study, AD treatment has increased more rapidly in people reporting good, rather than poor, mental health, 7 raising the possibility that AD use may be increasing in people with less severe mood disorders. Alternatively, advances in pharmacotherapy may be facilitating improved mental health among people with mood disorders that would otherwise be more severe, producing a similar pattern in the data. Nevertheless, there remains a component of the population that did not report AD treatment despite indicating that they were depressed for a large proportion of the preceding year. Future research will be needed to determine why this continues to occur.
These results indicate that the frequency of AD use among people with past-year MDEs is no longer increasing. This may be a positive indication that the need for these medications in the population is becoming saturated as the treatment frequency has increased. Conversely, this may represent a limited capacity of the health system, low levels of mental health literacy, stigma, or an impact of regulatory warnings that occurred in 2004. 8 Epidemiologic studies with a better capacity to assess need for treatment will be required to determine the true extent of under-or overtreatment in the population.
Résumé : La fréquence d'utilisation des antidépresseurs en relation avec les épisodes dépressifs majeurs récents et passés
Objectif : Il y a eu une tendance à une utilisation croissante des antidépresseurs (AD) dans les dernières décennies. Nous avons utilisé les données de l'Enquête nationale sur la santé de la population (ENSP) pour déterminer si cette tendance se poursuit et pour obtenir des estimations à jour de la fréquence d'utilisation.
Méthodes : L'ENSP est une enquête longitudinale sur la santé générale qui a commencé à recueillir des données en 1994. L'ENSP évalue les épisodes dépressifs majeurs (EDM) de l'année précédente à l'aide d'un instrument diagnostique abrégé. À chaque entrevue semestrielle (de 1994 à 2006), l'utilisation de médicaments actuelle est consignée. Nous avons estimé la fréquence à laquelle les répondants (de 12 ans et plus) prenaient des AD avec et sans EDM l'année précédente. Ces fréquences ont été croisées selon le sexe, l'année de l'entrevue, et la durée déclarée des symptômes.
Résultats :
Les AD sont pris par environ 5,4 % de la population des ménages en tout temps. La plupart des répondants prenant des AD n'ont pas déclaré d'EDM l'année précédente, mais 63,9 % des répondants prenant des AD sans épisode l'année précédente ont déclaré des épisodes antérieurs ou avoir reçu un diagnostic de dépression par un professionnel de la santé. Ce modèle est conforme au traitement à long terme pour la prévention d'une rechute. La fréquence globale d'utilisation des AD s'accroît seulement chez les répondants sans épisode l'année précédente.
Conclusions : L'utilisation des AD chez les résidents d'une collectivité ayant eu un EDM l'année précédente ne s'accroît plus. L'augmentation continue de la fréquence globale d'utilisation peut suggérer des indications élargies du traitement aux AD et peut indiquer que les gens prennent ces médicaments plus longtemps.
